Rasmus Holm-Jorgensen
Director of Finance/CFO presso ACRIVON THERAPEUTICS, INC.
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Rasmus Holm-Jorgensen founded Kiniksa Pharmaceuticals Ltd.
in 2015, where he worked as Chief Strategy & Portfolio Officer from 2015 to 2022.
Mr. Holm-Jorgensen also currently works at Acrivon Therapeutics, Inc., as Chief Financial Officer from 2022.
Mr. Holm-Jorgensen also formerly worked at Synageva BioPharma Corp., as Group Vice President & General Manager from 2011 to 2015.
Mr. Holm-Jorgensen received his graduate degree from the University of Copenhagen.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 14/02/2024 | 318 226 ( 1.03% ) | 2 M $ | 31/03/2024 |
Posizioni attive di Rasmus Holm-Jorgensen
| Società | Posizione | Inizio |
|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Director of Finance/CFO | 01/04/2022 |
Precedenti posizioni note di Rasmus Holm-Jorgensen
| Società | Posizione | Fine |
|---|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Founder | 01/04/2022 |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | 01/01/2015 |
Formazione di Rasmus Holm-Jorgensen
| University of Copenhagen | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| Aziende private | 2 |
|---|---|
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
| Acrivon Therapeutics, Inc. |
- Borsa valori
- Insiders
- Rasmus Holm-Jorgensen
